RS Oncology is a preclinical stage biotechnology company based in Cambridge, MA and London, UK with a mission to bring exciting new SCIENCE, through an INNOVATIVE BUSINESS model to PATIENTS who will have the best chance of benefiting from these new therapies. RSO is currently developing novel therapies that modulate mitochondrial pathways that drive diseases of oxidative stress, focusing initially on cancer.
What We Do
RS Oncology is currently developing novel therapeutics which modulate mitochondrial pathways that drive diseases of oxidative stress. Our lead program is currently focused on malignant mesothelioma and ovarian cancers. Over the past several years, two academic research teams working via sponsored research agreements with RS Oncology have developed the key proof-of-concept, pre-clinical data demonstrating the ability of the therapy to significantly reduce tumor burden in mice harboring malignant mesothelioma tumors. Collaborative work between the laboratories has determined the molecular mechanism for inhibition of the principal antioxidant pathway in mitochondria and the ability of the lead compound to irreversibly inactivate this pathway. Research to-date has identified key features of the compounds, targets and cellular environment that significantly influence specificity and efficacy. This important feature underlies the potent activity and therapeutic window observed in pre-clinical studies. Importantly, this protein target is dysregulated in most cancer types. Thus, inhibition of the protein has broad applicability and therapeutic potential for cancer therapy. Most notably treatments using this unique MOA can be guided by a companion diagnostic identifying patients with sufficiently dysregulated metabolic pathways prone to respond to therapy. RS Oncology is also dedicated to the development of a biomarker which can result in a companion diagnostic test. RS Oncology envisions a disease-agnostic approach (treat the biomarker, not the disease) in treating patients with this novel therapeutic approach.
Chief Executive Officer & General Counsel
Mr. Duncan co-founded RS Oncology in 2017 in collaboration with an academic laboratory that made the underlying scientific discovery. Mr. Duncan previously practiced in a large New England law firm and lead an acquisitions team for a large insurance company. He also has significant experience in developing successful innovative technologies to combat air and water pollution. Mr. Duncan is a graduate of the University of Massachusetts, Amherst and Vermont Law School and is a licensed attorney in Massachusetts and New Hampshire.
George Naumov, Ph.D.
Chief Operations Officer & Head of Business Development
Dr. George Naumov is the COO and Head of Business Development at RS Oncology. Dr. Naumov was previously the head of Clinical Science at Karyopharm Therapeutics Inc, Newton MA. He was involved with the development and approval of Selinexor (Xpovio), a first in class SINE XPO1 antagonist. Dr. Naumov was a management consultant with the DavCard Group and MedPharma Partners and has over 15 years of pharma/biotech consulting experience. He was a cofounder, President & CEO of Zateras Therapeutics Inc., a Boston based startup. Previously he was a Sr. Research Biologist in Oncology at Merck & Co and a scout for Merck Venture Fund. He holds a B.Sci. (Hon.) in biochemistry from Queen’s University at Kingston and a Ph.D. in Medical Biophysics from the University of Western Ontario, Canada. He ran a laboratory under Dr. Judah Folkmans at Harvard Medical School and Children’s Hospital Boston. He is widely published in the field of oncology. During his career, George has built a scientific and business brand of collaboration and innovation, both in academic and commercial settings.
Clinical Development Team
Alice Bexon, MD
Rodney Thompson, PhD
Nichole Pfeiffer Hicks
Patient Advocacy Liaison
Nichole Hicks is a 17+ year veteran in the non- profit space with leadership and operational expertise in national and global strategy, volunteer engagement, fundraising, partnerships and social causes. Prior to founding Creating Good Consulting in 2018, Nichole led the national strategy for youth and millennial engagement, and a top fundraising program for the American Cancer Society. Under her leadership, the program reached 700,000 students globally and raised over $50 million annually. Additionally, she has experience in design and implementation of volunteer structures, brand management, development of training programs and resources, communication strategies, partnerships and patient advocacy. Nichole is a recognized expert in developing collaborative national partnerships that maximize mission impact, and in exploring and implementing innovative fundraising and engagement opportunities. Her clients include ALSAC/St. Jude Children’s Research Hospital, The Patachou Foundation, Influences S|G and HALO Branded Solutions. She has contributed to webinars and articles on volunteer engagement and social cause for The Chronicle of Philanthropy and The Achieve Agency.
We’re happy to hear from you. Contact us today to learn more about our business and how you can benefit from working with us.